IDH2 and acute myeloid leukemia: Four [14, 25, 27, 28] articles (4 cohorts) reported CR with IDH inhibitors in R/R IDH-mutated AML patients, and our pooled CR rate was 21% [95% CI 0.18–0.24, I2 = 0%].